Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jukka Westermarck

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2020
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal ModelsHui Wei, Hui-Liang Zhang, Xiao-Chuan Wang, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 14, 2022
Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A SignalingWenting Hu, Zhuoqun Wang, Huiliang Zhang, et al.
Neurobiology of Aging|December 30, 2018
CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficitsYang-Ping Shentu, Wen-Ting Hu, Qing Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2021
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid LeukemiasEleonora Mäkelä, Karolina Pavic, Taru Varila, et al.
Molecular Oncology|July 17, 2023
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cellsOxana V Denisova, Joni Merisaari, Riikka Huhtaniemi, et al.
Cell Reports|August 4, 2015
Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative ProliferationKevin Myant, Xi Qiao, Tuuli Halonen, et al.
Molecular Cancer Therapeutics|April 1, 2022
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease SubtypeAnna N Cvrljevic, Umar Butt, Kaisa Huhtinen, et al.
Cell Reports|July 19, 2018
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's DiseaseYang-Ping Shentu, Yuda Huo, Xiao-Long Feng, et al.
Science Translational Medicine|July 20, 2018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cellsOtto Kauko, Caitlin M O'Connor, Evgeny Kulesskiy, et al.
Molecular Oncology|December 3, 2022
PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancersAnna Aakula, Aleksi Isomursu, Christian Rupp, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2020
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal ModelsHui Wei, Hui-Liang Zhang, Xiao-Chuan Wang, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 14, 2022
Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A SignalingWenting Hu, Zhuoqun Wang, Huiliang Zhang, et al.
Neurobiology of Aging|December 30, 2018
CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficitsYang-Ping Shentu, Wen-Ting Hu, Qing Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2021
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid LeukemiasEleonora Mäkelä, Karolina Pavic, Taru Varila, et al.
Molecular Oncology|July 17, 2023
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cellsOxana V Denisova, Joni Merisaari, Riikka Huhtaniemi, et al.
Cell Reports|August 4, 2015
Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative ProliferationKevin Myant, Xi Qiao, Tuuli Halonen, et al.
Molecular Cancer Therapeutics|April 1, 2022
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease SubtypeAnna N Cvrljevic, Umar Butt, Kaisa Huhtinen, et al.
Cell Reports|July 19, 2018
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's DiseaseYang-Ping Shentu, Yuda Huo, Xiao-Long Feng, et al.
Science Translational Medicine|July 20, 2018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cellsOtto Kauko, Caitlin M O'Connor, Evgeny Kulesskiy, et al.
Molecular Oncology|December 3, 2022
PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancersAnna Aakula, Aleksi Isomursu, Christian Rupp, et al.
Pageof 10